glp-1 obesity drug news today 2025-10-20 A second helping of weight-loss drugs is coming GLP-1 trends 2025: real-world data,

[DOI] [PMC free article] [PubMed] [Google Scholar] 13.Jackson R.M., Gupta C

Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories

Pretreatment with these agents successfully reduces serum transaminase levels and histopathological liver alterations

The most commonly reported adverse events associated with the use of dihydroergotamine mesylate nasal spray during placebo-controlled, double-blind studies for the treatment of migraine headache and not reported at an equal incidence by placebo-treated patients were rhinitis, altered sense of taste, application site reactions, dizziness, nausea, and vomiting

Omega-3 supplementation seems to be an option that can be effective in improving the lipid profile and reducing cardiovascular risk, as metabolic nuclear receptors like PPAR and SREBP-1 (sterol regulatory element-binding protein 1) are activated by the binding of natural lipid-derived ligands such as fatty acids, allowing the inhibition of protein-coding that stimulates lipid synthesis and genes that increase lipid oxidation in the liver and muscle